Shopping Cart (0)
My Account

 Shopping Cart
Conferences | Training Courses | Market Reports | Managed Events | Past Conferences | Update Me
SELECTBIO Conferences Antibodies in Drug Discovery
Conferences  \  Antibodies in Drug Discovery
RegisterLogin

Antibodies in Drug Discovery

Date: Tuesday, 9 February 2016 - Wednesday, 10 February 2016
Location: Cambridge, UK

Keynote Speakers

Paul Insel

Paul Insel
Vice-Chair and Distinguished Professor, Pharmacology, University of California San Diego

John McCafferty

John McCafferty
Founder & CEO, IONTAS Ltd

Christian Klein

Christian Klein
Expert Scientist/Head, Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich

Overview

SELECTBIO is pleased to announce Antibodies in Drug Discovery 2016, which will be held on 9 - 10 February 2016 in Cambridge, UK. The event is part of our Cambridge Workshop Series.

Attracting researchers, academics and industry professionals working in antibody research, this event will fully explore the latest developments in the design and engineering of antibodies in relation to the burgeoning field of biotherapeutics. Topics to be addressed include, engineering challenges and techniques, new technologies and business hurdles when developing antibodies, the latest developments in autoimmune and infectious disease research.

As a result of a major shift in focus of many pharmaceutical companies from small molecules to a portfolio that contains protein and chemical therapeutic agents, rapid progress has been made in the area of antibodies for drug discovery.

If you work in antibody drug discovery research you will benefit from the expert knowledge of academic and industry leaders who are pushing the boundaries of antibody discovery, whilst networking with the technology providers who are enabling them to do so.
Session Sponsors

Agenda Topics

  • Antibody Drug Conjugates (ADCs)
  • CAR/CAR-T Cells
  • Humanised Single Domain Antibodies for Research and Therapeutic Applications
  • Novel Immune Check Point Therapeutics, PD1 and Beyond
  • Patented Antibodies and Related Technologies in Europe
  • Targeting Ion Channels with Biologics

Sponsorship and Exhibition Opportunities

Exhibition Team,
exhibitors@selectbio.com
+44 (0) 1206 501654

Confirmed Speakers to date

Roger Beerli, CSO, NBE Therapeutics
John Castle, Executive Director, Vaccine Research and Translational Medicine, Agenus Switzerland Inc.
Patrick Chames, Main Scientist, INSERM
Steve Davenport, VP European Sales, Intellicyte
Mahendra Deonarain, Chief Science & Operating Officer, Antikor Biopharma Ltd
Stefan Dubel, Full Professor and Director, Technische Universität Braunschweig
Trevor Hallam, Chief Scientific Officer, Sutro Biopharma Inc
Roman Kischel, Principal Scientist, Amgen Research
John Li, Senior Scientist, MedImmune
Craig Malcolm, Strategic Collaborations Manager, Promega UK Ltd
Franck Perez, Group Leader, Institut Curie
Martin Pule, Director Chimeric Antigen Receptor (CAR) Programme. Founder & Chief Scientific Officer, UCL Autolus
Lioudmila Tchistiakova, Senior Director, Pfizer Inc
Tristan Vaughan, Vice President, R&D, Antibody Discovery and Protein Engineering, MedImmune Ltd
Stefan Weigand, Head of Large Molecule Research, F. Hoffmann-La Roche Ltd
Robert Williams, Chief Drug Development Scientist, Cancer Research UK
Paul Wylie, Product Manager, TTP LabTech Ltd

Corporate Sponsors Media Sponsors Networking
U-Networks

Add to Calendar ▼2016-02-09 00:00:002016-02-10 00:00:00Europe/LondonAntibodies in Drug DiscoveryAntibodies in Drug Discovery in Cambridge, UKCambridge, UKSELECTBIOenquiries@selectbiosciences.com


Corporate Sponsors